Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Christmas is fast approaching and the atmosphere on stock markets is rather joyful, with most indices in the green. Investors are cheering fresh data showing a slowdown in eurozone inflation in... -December 19, 2023 at 09:30 am EST - MarketScreener
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Kronos Bio Stock (NASDAQ: KRON) stock price, news, charts, stock research, profile.
Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the company has decided not to
Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New...